Clinical trialNCT06990880RecruitingPhase 1/PHASE2Interventional

A Study of GSK5458514 Administered Alone or In Combination With Other Anti-Cancer Agents in Participants With Prostate Cancer

SponsorGlaxoSmithKlineEnrollment85Neoplasms, Prostate

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The goal of the study is to evaluate how safe and how well the body handles GSK5458514 when administered in participants with prostate cancer. The study will be conducted in two parts - Part 1 (dose escalation phase) and Part 2 (dose expansion phase).

clinicaltrials.gov ↗

Investigators

No overall officials are registered on this study record. Site-level investigators, where published, appear with their sites below. Why? →

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

19 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Canada

Gsk Investigational Site
Montreal, Quebec, Canada
April Rose
Recruiting
Gsk Investigational Site
Montreal, Quebec, Canada
Ramy Saleh
Recruiting

France

Gsk Investigational Site
Lyon, France
Armelle Vinceneux
Recruiting
Gsk Investigational Site
Villejuif, France
Yohann Loriot
Recruiting

Japan

Gsk Investigational Site
Kanagawa, Japan
Takashi Kawahara
Recruiting
Gsk Investigational Site
Tokyo, Japan
Tatsunori Shimoi
Recruiting
Gsk Investigational Site
Tokyo, Japan
Yuji Miura
Recruiting

Spain

Gsk Investigational Site
Badajoz, Spain
Marta González Cordero
Recruiting
Gsk Investigational Site
Barcelona, Spain
Tatiana Hernandez
Recruiting
Gsk Investigational Site
Madrid, Spain
Bernard Doger
Recruiting
Gsk Investigational Site
Madrid, Spain
Emiliano Calvo Aller
Recruiting
Gsk Investigational Site
Málaga, Spain
Lucia Oliva Fernandez
Recruiting
Gsk Investigational Site
Pozuelo de AlarcOn Madr, Spain
VALENTINA BONI
Recruiting

United States

Gsk Investigational Site
Phoenix, Arizona, United States
Yousef Zakharia
Recruiting
Gsk Investigational Site
Denver, Colorado, United States
Gerald Falchook
Recruiting
Gsk Investigational Site
New Haven, Connecticut, United States
Daniel Petrylak →
Recruiting
Gsk Investigational Site
Rochester, Minnesota, United States
Dan Childs
Recruiting
Gsk Investigational Site
East Brunswick, New Jersey, United States
Bruno Fang
Recruiting
Gsk Investigational Site
Nashville, Tennessee, United States
Benjamin Garmezy
Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

GSK5458514

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 12 Jun 2025
Primary completion: 26 Oct 2027
Completion: 9 Aug 2028
Last update posted: 18 Jun 2026
Registered enrollment: 85
Registry id: NCT06990880

Cross-registrations

EU-CTR / CTIS (EudraCT)2025-521581-10

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.